SecBot SecBot
SECBOTREPLAY Home › Report › ALNY

ALNY · Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed…

ALNYLAM PHARMACEUTICALS, INC. · 8-K filed Jul 30, 2026 at 08:06 ET

At the news

BEARISHIMPACT 7/10

8-K filed Jul 30, 2026 at 08:06 ET

Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed consensus of $2.15 by 14.5%) and total revenue of $1.291B (missed $1.32B consensus by 2.2%). The company lowered its full-year 2026 TTR net product revenue guidance from $4.4B-$4.7B to $4.2B-$4.5B, citing normalization of second-line demand after an initial pent-up launch surge. Despite strong 74% YoY product revenue growth, the guidance cut and earnings miss signal a slower-than-expected ATTR-CM launch trajectory.

  • Q2 2026 total revenues $1.291B (+67% YoY), net product revenues $1.172B (+74% YoY)
  • GAAP diluted EPS $1.21; non-GAAP diluted EPS $1.84 (missed consensus of $2.15 by 14.5%)
  • Total TTR net product revenues $1.030B (+89% YoY), driven by AMVUTTRA sales of $1.012B (+106% YoY)
  • Full-year 2026 TTR revenue guidance lowered to $4.2B-$4.5B from $4.4B-$4.7B; total product revenue guidance lowered to $4.7B-$5.1B from $4.9B-$5.3B

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access